1. Home
  2. VRAX vs GRNQ Comparison

VRAX vs GRNQ Comparison

Compare VRAX & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • GRNQ
  • Stock Information
  • Founded
  • VRAX 2013
  • GRNQ 2013
  • Country
  • VRAX United Kingdom
  • GRNQ Malaysia
  • Employees
  • VRAX N/A
  • GRNQ N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GRNQ EDP Services
  • Sector
  • VRAX Health Care
  • GRNQ Technology
  • Exchange
  • VRAX Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • VRAX 7.3M
  • GRNQ 8.9M
  • IPO Year
  • VRAX 2022
  • GRNQ 2018
  • Fundamental
  • Price
  • VRAX $1.80
  • GRNQ $1.06
  • Analyst Decision
  • VRAX
  • GRNQ
  • Analyst Count
  • VRAX 0
  • GRNQ 0
  • Target Price
  • VRAX N/A
  • GRNQ N/A
  • AVG Volume (30 Days)
  • VRAX 230.2K
  • GRNQ 335.9K
  • Earning Date
  • VRAX 02-05-2025
  • GRNQ 03-27-2025
  • Dividend Yield
  • VRAX N/A
  • GRNQ N/A
  • EPS Growth
  • VRAX N/A
  • GRNQ N/A
  • EPS
  • VRAX N/A
  • GRNQ N/A
  • Revenue
  • VRAX $84,872.00
  • GRNQ $2,727,344.00
  • Revenue This Year
  • VRAX $5,169.18
  • GRNQ N/A
  • Revenue Next Year
  • VRAX $66.97
  • GRNQ N/A
  • P/E Ratio
  • VRAX N/A
  • GRNQ N/A
  • Revenue Growth
  • VRAX 7.03
  • GRNQ N/A
  • 52 Week Low
  • VRAX $0.60
  • GRNQ $0.80
  • 52 Week High
  • VRAX $9.00
  • GRNQ $2.24
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 43.63
  • GRNQ 49.42
  • Support Level
  • VRAX $1.56
  • GRNQ $0.97
  • Resistance Level
  • VRAX $1.86
  • GRNQ $1.28
  • Average True Range (ATR)
  • VRAX 0.20
  • GRNQ 0.08
  • MACD
  • VRAX -0.05
  • GRNQ -0.01
  • Stochastic Oscillator
  • VRAX 32.05
  • GRNQ 37.40

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management, cross-border listing advisory services, and transaction services. It also operates a venture capital business. Its segments include Service business engaged in the provision of corporate advisory and business solution services; and Real estate business engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia.

Share on Social Networks: